- Home
- ZBH vs INCY Comparison
ZBH vs INCY Comparison
Compare ZBH & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBH
- INCY
- Stock Information
- Founded
- ZBH 1927
- INCY 1991
- Country
- ZBH United States
- INCY United States
- Employees
- ZBH N/A
- INCY N/A
- Industry
- ZBH Industrial Specialties
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ZBH Health Care
- INCY Health Care
- Exchange
- ZBH Nasdaq
- INCY Nasdaq
- Market Cap
- ZBH 20.0B
- INCY 17.0B
- IPO Year
- ZBH N/A
- INCY 1993
- Fundamental
- Price
- ZBH $98.79
- INCY $86.60
- Analyst Decision
- ZBH Buy
- INCY Buy
- Analyst Count
- ZBH 18
- INCY 20
- Target Price
- ZBH $112.88
- INCY $80.67
- AVG Volume (30 Days)
- ZBH 1.3M
- INCY 1.7M
- Earning Date
- ZBH 11-05-2025
- INCY 10-28-2025
- Dividend Yield
- ZBH 0.97%
- INCY N/A
- EPS Growth
- ZBH N/A
- INCY 900.04
- EPS
- ZBH 4.11
- INCY 4.37
- Revenue
- ZBH $7,833,800,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- ZBH $8.18
- INCY $16.41
- Revenue Next Year
- ZBH $5.91
- INCY $10.86
- P/E Ratio
- ZBH $24.10
- INCY $19.96
- Revenue Growth
- ZBH 4.11
- INCY 18.87
- 52 Week Low
- ZBH $89.22
- INCY $53.56
- 52 Week High
- ZBH $114.72
- INCY $88.66
- Technical
- Relative Strength Index (RSI)
- ZBH 44.82
- INCY 59.14
- Support Level
- ZBH $96.06
- INCY $85.18
- Resistance Level
- ZBH $101.31
- INCY $88.27
- Average True Range (ATR)
- ZBH 2.16
- INCY 1.89
- MACD
- ZBH -0.19
- INCY 0.02
- Stochastic Oscillator
- ZBH 35.06
- INCY 75.54
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.